TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21714932

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 4002

Group type: COMPARATOR
Intervention: Diet plus pravastatin
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4002
Study: 19236622

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood glucose > 8.0 mmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood glucose <= 8.0 mmol/l
Number of subjects: 0
Study: 16551889

Group type: EXPERIMENTAL
Intervention: Antithrombin (3000 U infused over 30 min before heparin administration and 24 h later)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no antithrombin infusion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 16
Study: 14535902

Group type: EXPERIMENTAL
Intervention: Oral midazolam 1.5 mg x kg(‐1)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard-dose midazolam (0.5-1.0 mg x kg(‐1))
Number of subjects: 193
Study: 10700758

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of perforated peptic ulcers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open repair of perforated peptic ulcers
Number of subjects: 36
Study: 9376645

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin at 20:00 h on Days 1 to 15 (Melatonin 1st)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo on Days 16 to 30 (Placebo 2nd)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Melatonin 2nd
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo 1st
Number of subjects: 10
Study: 7902484

Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (180 or 360 mg during 6 or 9 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (45 mg every 3 months for 1 year)
Number of subjects: 20
Study: 6780266

Group type: EXPERIMENTAL
Intervention: Early CPAP (FIO2 = 0.3, PO2 > 50 torr) at a mean age of 7.1 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Late CPAP (FIO2 = 0.5, PO2 > 50 torr) at a mean age of 15.1 hours
Number of subjects: 38
Study: 31493344

Group type: EXPERIMENTAL
Intervention: Closed-form and iterative formulas for sample size determination for hierarchical data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulas for a four-level hierarchical linear model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indices impacting standard errors (e.g., random intercept or slope variance at each level)
Number of subjects: 0
Study: 31812311

Group type: EXPERIMENTAL
Intervention: CGBH-soaked pharyngeal packing
Number of subjects: 101

Group type: COMPARATOR
Intervention: Saline-soaked pharyngeal packing
Number of subjects: 101
Study: 28386783

Group type: EXPERIMENTAL
Intervention: Dexamethasone, total dose of 30 mg perioperatively
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no glucocorticoid)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 110
Study: 25886492

Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (TPDS)
Number of subjects: 3408

Group type: EXPERIMENTAL
Intervention: Non-Tailored Personalised Decision Support (NTPDS)
Number of subjects: 3408

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 3408

Group type: EXPERIMENTAL
Intervention: Tailored Personalised Decision Support (TPDS) and Non-Tailored PDS (NTPDS)
Number of subjects: 3408

Group type: EXPERIMENTAL
Intervention: Tailored messaging
Number of subjects: 3408
Study: 23596788

Group type: EXPERIMENTAL
Intervention: Modified Taohe Chengqi Granule (MTCG) combined with intravenous dripping of mannitol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous dripping of mannitol alone
Number of subjects: 64
Study: 21233806

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle school-based obesity intervention program
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard health curriculum (Control)
Number of subjects: 450
Study: 19384225

Group type: EXPERIMENTAL
Intervention: Nasoduodenal (ND) feedings
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nasogastric (NG) feedings
Number of subjects: 121
Study: 17192498

Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as solution to the distal ileum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as solution to the ascending colon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered as powder to the ascending colon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fasudil HCl administered orally as an immediate-release tablet
Number of subjects: 10
Study: 17141633

Group type: EXPERIMENTAL
Intervention: Multilevel botulinum toxin type A (BTX‐A) and comprehensive rehabilitation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual physical therapy (PT)
Number of subjects: 46
Study: 14663611

Group type: EXPERIMENTAL
Intervention: Saline‐irrigated cooled‐tip radiofrequency ablation (SICTRA)
Number of subjects: 113
Study: 10355394

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Uncoated circuit (control group)
Number of subjects: 350
Study: 7739262

Group type: EXPERIMENTAL
Intervention: Video-assisted lobectomy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Muscle-sparing thoracotomy and lobectomy
Number of subjects: 61
Study: 2166720

Group type: EXPERIMENTAL
Intervention: N-methylformamide (N-MF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: spirogermanium
Number of subjects: 54
Study: 6756828

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 74
Study: 31012215

Group type: EXPERIMENTAL
Intervention: Rectal barostat study (follow-up after 8-12 years)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IBS-QOL assessment (follow-up after 8-12 years)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Assessment of anxiety, depression, IBS symptom severity, or somatization (follow-up after 8-12 years)
Number of subjects: 26
Study: 28074804

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 25954849

Group type: EXPERIMENTAL
Intervention: Individualized heparin management (IHM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional hemostasis management (CHM)
Number of subjects: 120
Study: 23962470

Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 10 mg with 0.5% bupivacaine 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg with 0.5% bupivacaine 10 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal tramadol 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg
Number of subjects: 80
Study: 21372608

Group type: EXPERIMENTAL
Intervention: Metformin + lifestyle (ML)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo + lifestyle (PL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metformin (in vitro)
Number of subjects: 22
Study: 17923328

Group type: EXPERIMENTAL
Intervention: Intra-articular ketamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study: 17135672

Group type: EXPERIMENTAL
Intervention: Escherichia coli-derived lipopolysaccharide (LPS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae-derived 1,3 beta-glucan (BGL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Combination of LPS + BGL
Number of subjects: 2

Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 2
Study: 12707865

Group type: EXPERIMENTAL
Intervention: Cold pressor pain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 100
Study: 10764171

Group type: EXPERIMENTAL
Intervention: Intranasal PCA with fentanyl (25 microg bolus, lockout interval 6 min)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous PCA with fentanyl (17.5 microg bolus, lockout interval 6 min)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (Intranasal and Intravenous PCA)
Number of subjects: 48
Study: 8827547

Group type: EXPERIMENTAL
Intervention: Artificial surfactant therapy for hyaline membrane disease (HMD)
Number of subjects: 0
Study: 1599072

Group type: EXPERIMENTAL
Intervention: 50 mg of pethidine added to 9 ml of 0.25% bupivacaine
Number of subjects: 49

Group type: COMPARATOR
Intervention: 1 ml of saline (control)
Number of subjects: 49
Study: 6486080

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg, two daily doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31517849

Group type: EXPERIMENTAL
Intervention: Not applicable; systematic review and meta-analysis of existing studies
Number of subjects: 0
Study: 29985782

Group type: EXPERIMENTAL
Intervention: Gain-framed auditory message
Number of subjects: 258

Group type: COMPARATOR
Intervention: Gain-framed written message
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Loss-framed auditory message
Number of subjects: 258

Group type: COMPARATOR
Intervention: Loss-framed written message
Number of subjects: 258
Study: 27716290

Group type: EXPERIMENTAL
Intervention: rtfMRI Neurofeedback Training (NFT) in addition to treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 24777150

Group type: EXPERIMENTAL
Intervention: Esomeprazole IV bolus at a dose of 80 mg plus infusion at 8 mg/h for 72 h and oral placebo every 12 h (IVP group)
Number of subjects: 244

Group type: COMPARATOR
Intervention: High-dose oral esomeprazole at a dose of 40 mg every 12 h (ORP group)
Number of subjects: 244
Study: 23126645

Group type: EXPERIMENTAL
Intervention: Combined simvastatin 40 mg and ezetimibe 10 mg daily
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1418
Study: 20043083

Group type: EXPERIMENTAL
Intervention: Indomethacin (NSAID) for 3 days before surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Indomethacin (NSAID)
Number of subjects: 23
Study: 16936703

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 34
Study: 16260201

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study: 11300382

Group type: EXPERIMENTAL
Intervention: High dose L-arginine (n=10)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low dose L-arginine (n=10)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 35
Study: 9448657

Group type: EXPERIMENTAL
Intervention: risperidone (6-16 mg/day)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: risperidone (2 mg/day)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 513

Group type: COMPARATOR
Intervention: haloperidol (20 mg/day)
Number of subjects: 513

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 513
Study: 7939440

Group type: EXPERIMENTAL
Intervention: Intracavernous injection therapy with papaverine/phentolamine (n = 172 evaluable)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Venous surgery (n = 134 evaluable)
Number of subjects: 603
Study: 3145948

Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam taken the night before surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 20
Study: 29493385

Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) added to standard pegylated interferon and ribavirin (PEG‐IFN/RBV)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard pegylated interferon and ribavirin (PEG‐IFN/RBV) alone
Number of subjects: 31
Study: 28679180

Group type: EXPERIMENTAL
Intervention: Curcumin and Calendula suppositories (350 mg Curcumin, 80 mg Calendula, 1 suppository/day for 1 month)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1 suppository/day for 1 month)
Number of subjects: 60
Study: 26039929

Group type: EXPERIMENTAL
Intervention: Patient-selected care buddy (PSCB)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1209
Study: 23943213

Group type: EXPERIMENTAL
Intervention: Dynamic cerebral autoregulation (CA) measured by transfer function phase on day 5
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dynamic CA measured by gain
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dynamic CA measured by phase
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dynamic CA measured by phase on day 1
Number of subjects: 26
Study: 21288520

Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 91
Study: 18186996

Group type: EXPERIMENTAL
Intervention: Bulb syringe self-treatment with ear drops and instructions
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional irrigation by GP or practice nurse with ear drops
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Bulb syringe self-treatment
Number of subjects: 237

Group type: COMPARATOR
Intervention: Conventional irrigation
Number of subjects: 237
Study: 17001115

Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2222 (conductive area/total area: 2.00/10.24 cm2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2271 (conductive area/total area: 2.54/29.64 cm2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2660 (conductive area/total area: 11.64/11.64 cm2)
Number of subjects: 12
Study: 14693310

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (IFNβ‐1a) 30 μg IM once weekly
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 10595879

Group type: EXPERIMENTAL
Intervention: Wire-guided cricothyrotomy technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard surgical cricothyrotomy technique
Number of subjects: 15
Study: 8767567

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (10 Hz)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (50 Hz)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control stimulation (0.2 Hz)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (10 Hz and 50 Hz)
Number of subjects: 7
Study: 1749978

Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IPA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous narcotics
Number of subjects: 39
Study: 6195981

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 1,000 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25% albumin 200 ml
Number of subjects: 20
Study: 31242512

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 29496058

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) lymphangiography, 2.5mg injected submucosally and subdermally
Number of subjects: 22
Study: 27336154

Group type: EXPERIMENTAL
Intervention: Vitamin D3-supplemented yogurt (VDY) drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain yogurt
Number of subjects: 0
Study: 24556626

Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum-based regimens)
Number of subjects: 535
Study: 22878381

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (CLs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monofocal contact lenses (CLs)
Number of subjects: 30
Study: 20507560

Group type: EXPERIMENTAL
Intervention: Improved dining atmosphere, greater food choice, extended restaurant hours, readily available snacks and drinks machines
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control homes maintained previous food and drink provision system
Number of subjects: 120
Study: 18257182

Group type: EXPERIMENTAL
Intervention: Acup‐moxibustion treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral administration of 50 mg Clomiphene
Number of subjects: 120
Study: 15766996

Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg once daily)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with every levodopa dose)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 12829862

Group type: EXPERIMENTAL
Intervention: Surgically treated patients
Number of subjects: 2885

Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Both medically and surgically treated patients
Number of subjects: 2885

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhages (PTI, ICH, SAH)
Number of subjects: 2885
Study: 10888476

Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 I.U.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 15
Study: 7725125

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six sessions including support, problem-solving, and coping skills)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 80
Study: 2040104

Group type: EXPERIMENTAL
Intervention: Piroxicam 0.5% gel (5 mg q.i.d.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 200
Study: 7325344

Group type: EXPERIMENTAL
Intervention: Combination of peridural anaesthesia and neuroleptanalgesia (PDA/NLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane anaesthesia with intubation
Number of subjects: 20
Study: 6404603

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 43
Study: 30248102

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 250
Study: 26840669

Group type: EXPERIMENTAL
Intervention: Oromotor stimulation along with routine care (n=25)
Number of subjects: 51
Study: 24734244

Group type: EXPERIMENTAL
Intervention: Personalized instruction
Number of subjects: 38

Group type: COMPARATOR
Intervention: Video-based instruction
Number of subjects: 38
Study: 22235969

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (mock treatment)
Number of subjects: 178
Study: 20070642

Group type: EXPERIMENTAL
Intervention: Dual-panel (DP) methodology
Number of subjects: 200

Group type: COMPARATOR
Intervention: Forward-backward (FB) methodology
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both versions (FB and DP)
Number of subjects: 200
Study: 19099547

Group type: COMPARATOR
Intervention: 0.5-2% chitin-glucan applied twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1.5% chitin-glucan formulation applied twice daily
Number of subjects: 33
Study: 15780532

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 95
Study: 12417278

Group type: EXPERIMENTAL
Intervention: Vitamin C administration
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Maximal exercise (Control)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Submaximal exercise
Number of subjects: 31
Study: 10356076

Group type: EXPERIMENTAL
Intervention: (n-3) fatty acid supplementation (approximately 5.2 g (n-3) fatty acids)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control oil period (COP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline period (BLP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: (n-3) fatty acid supplementation
Number of subjects: 11
Study: 7594152

Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 197
Study: 1723455

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg once daily
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 7472173

Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 10 mg/kg orally
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 15 mg/kg intramuscularly
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 5 mg/kg orally or intramuscularly
Number of subjects: 41
Study: 31380297

Group type: EXPERIMENTAL
Intervention: Probiotic administration
Number of subjects: 32
Study: 28366435

Group type: EXPERIMENTAL
Intervention: omalizumab 300mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: omalizumab 150mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 218
Study: 25851155

Group type: EXPERIMENTAL
Intervention: Chitin microparticles (CP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lipopolysaccharide (LPS)
Number of subjects: 14
Study: 23380438

Group type: EXPERIMENTAL
Intervention: PRM‐151 (10 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRM‐151
Number of subjects: 8
Study: 21713778

Group type: EXPERIMENTAL
Intervention: Imatinib adjuvant therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Follow-up alone (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuation Imatinib treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Interruption treatment (Control)
Number of subjects: 90
Study: 18832751

Group type: EXPERIMENTAL
Intervention: rHDL (80 mg/kg given over 4 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20